Keytruda (Pembrolizumab) and Lenvima (Lenvatinib) Treatment Regimen
In this article
What Is Pembrolizumab + Lenvatinib?
Pembrolizumab + lenvatinib combines PD-1 blockade with anti-VEGFR/FGFR TKI activity. Its main uses are:
1) Advanced endometrial carcinoma (pMMR or non-MSI-H) after prior systemic treatment in adults who are not candidates for curative surgery/RT;
2) Advanced/metastatic RCC in the first-line setting. Efficacy was demonstrated in the Phase III trials KEYNOTE-775 (EC) and CLEAR/KEYNOTE-581 (RCC).
⚙️ How Does It Work?
- Pembrolizumab: Blocks PD-1/PD-L1 interaction, increasing T-cell activation → stronger antitumor immunity.
- Lenvatinib: Inhibits VEGFR-1/2/3, FGFR-1/2/3/4, PDGFR-α, RET and KIT; reduces angiogenesis and the immunosuppressive microenvironment.
- Synergy: Vessel normalization + increased T-cell infiltration ↑ → enhanced PD-1 blockade.
🎯 Treatment Goals
🧬 Tumor Control
Immune checkpoint blockade + antiangiogenic suppression increase objective response and disease control rates.
⏳ Delaying Progression (PFS)
RCC (CLEAR): Median PFS: 23.9 months vs sunitinib 9.2 months (HR 0.39).
📊 Extending Overall Survival (OS)
- EC (KEYNOTE-775): Median OS in the pMMR population: 17.4 vs 12.0 months (HR 0.68); ITT: 18.3 vs 11.4 months (HR 0.62).
- RCC (CLEAR): OS superior to sunitinib (initial analysis HR 0.66); the benefit persisted at long-term follow-up.
🌿 Quality of Life
Lower symptom burden and reduced steroid requirements may help maintain daily activities .
🧾 Treatment Indications & Guideline Position
✅ Approved Indications
- Endometrial Carcinoma (EC): pMMR or non-MSI-H; after prior systemic treatment in adults ineligible for curative surgery/RT.
- RCC (1st Line): Across all IMDC risk groups, pembrolizumab + lenvatinib is among the preferred options.
📚 Guideline Note
In endometrial carcinoma, first-linetreatment with pembrolizumab + carboplatin/paclitaxel is separately approved; pembro+lenva is used mainly after platinum treatment.
💉 Dose and Administration Schedule
| Component | Standard Dose | Interval | Administration | Duration |
|---|---|---|---|---|
| Pembrolizumab | 200 mg or 400 mg | Every 3 weeks or every 6 weeks | IV infusion ~30 minutes | ≤ 24 months (progression/tolerance) |
| Lenvatinib | 20 mg/day | Daily | Oral (single dose; with or without food) | Until progression/unacceptable toxicity; after 2 years of combination treatment in RCC, may continue alone as monotherapy |
🔄 Administration Sequence
On the first day, give pembrolizumab infusion (≈30 minutes); the same day or next morning, start daily lenvatinib.
-
Take a single daily dose ; with or without food , at the same timeeach day. Swallow capsules whole (do not crush/chew). Patients unable to swallow may receive a suspension prepared in water or apple juice (through a feeding tube if needed).
-
If a dose is missed and the next dose is due in ≤12 hours , skip the missed doseand take the next dose at its usual time.
📌 Pretreatment Checks
- Blood pressure (including home measurements), TSH/fT4, AST/ALT/ALP/bilirubin, creatinine/eGFR, complete blood count
- Urine protein (dipstick ± 24 hours)
- HBV/HCV assessment; history of severe autoimmune disease/transplantation review
- If needed, ECG + electrolytes (QT risk; concomitant QT-prolonging medications)
- Pregnancy test and counseling on effective contraception .
Note: In severe kidney/liver impairment, the recommended starting dose of lenvatinib is 10 mg/day .
⚠️ Special Situations Requiring Attention
🩺 Hypertension & Proteinuria (Lenvatinib)
- Bring hypertension under control before starting ; during the first 2 months, monitor closely .
- G3 HT (despite optimal treatment): withhold/reduce dose; G4: permanently discontinue.
- Proteinuria ≥2 g/24 hours: withhold/reduce dose; nephrotic syndrome: permanently discontinue.
🧠 Immune-Related AEs (Pembrolizumab)
- Pneumonitis, colitis, hepatitis, nephritis and endocrinopathies (thyroiditis/hypophysitis/adrenal disorders) may occur.
- G2–3: withhold + systemic steroids; taper gradually after improvement. G4: permanently discontinue in most cases.
🩻 Surgery/Dental Procedures
- Withhold lenvatinib before planned major surgery, ≥1 week beforehand ;after major surgery, wait ≥2 weeks and until wound healing is complete before restarting.
👶 Pregnancy/Breastfeeding & QT
- Lenvatinib may cause embryo-fetal toxicity ; effective contraception is essential.
- QT prolongation risk: avoid concomitant QT-prolonging drugs; correct electrolytes and monitor ECG if needed.
🤒 Selected Side Effects
RCC – CLEAR: Any-grade AEs ≈ 100%; G≥3 AEs ≈ 82%. EC – KEYNOTE-775: G≥3 AEs ≈ 89%. Common events include hypertension, diarrhea, appetite/weight loss, proteinuria, hypothyroidism, mucositis and rash.
| Side Effect | Frequency (Summary) | Management (Label) |
|---|---|---|
| Hypertension (lenva) | Very common | G3: withhold/reduce dose; G4: discontinue |
| Proteinuria (lenva) | Common | ≥2 g/24 hours: withhold/reduce; nephrotic syndrome: discontinue |
| irAEs (pembro) | Common (highly variable) | G2–3: interrupt + steroids; G4: discontinue in most cases |
| Diarrhea/loss of appetite, HFSR, mucositis | Common | Symptomatic support + lenva dose reduction steps (14→10→8 mg) |
ℹ️ Important Note
Side effects vary between patients. When severe toxicity is suspected, early reporting and dose modification are critical for treatment continuity.
🔎 Follow-Up & Monitoring
| Parameter | Frequency | Threshold/Note |
|---|---|---|
| Blood pressure | After week 1, for 2 months, every 2 weeks, then at least monthly6 | G3: withhold/reduce; G4: discontinue |
| TSH/fT4 | Monthly | Hypothyroidism is common; replacement may be needed |
| Urine protein | Every 4–6 weeks | ≥2 g/24 hours: withhold/reduce |
| LFT/renal/complete blood count | Every 3–6 weeks | Withhold/reduce according to hepatic/renal toxicity |
| Imaging | Every 8–12 weeks | Earlier assessment if clinical deterioration occurs |
🧮 Dose Modification: Practical Thresholds
- Lenvatinib Reduction Steps: 20 → 14 → 10 → 8 mg/day (RCC/EC).
- HT (G3): withhold/reduce; G4: permanently discontinue. Proteinuria ≥2 g/24 hours: withhold/reduce; nephrotic syndrome: discontinue.
- Pembrolizumab: do not reduce the dose; G2–3 irAE → withhold + steroids; G4 → usually discontinue.
- Severe Kidney/Liver Impairment: Starting lenvatinib dose: 10 mg/day.
📌 Clinical Nuances
- Endometrial Carcinoma: Confirming pMMR is important; for MSI-H/dMMR disease, single-agent ICI options may also be considered.
- RCC: After completing 2 years of combination treatment, lenvatinib monotherapy may continue.
🔄 Drug Interactions
Pembrolizumab
- Conventional CYP-mediated interactions are not expected (monoclonal antibody).
- High-dose immunosuppressants (such as steroids) may reduce efficacy; for irAE management they are indicated.
Lenvatinib
- QT-prolonging drugs increase arrhythmia risk ↑; avoid if possible or monitor ECG + electrolytes.
- Anticoagulants/antiplatelets increase bleeding risk ↑ → monitor carefully.
- For planned surgery/dental procedures, follow the timing rulesabove.
📚 Sources
- Motzer RJ, et al. NEJM 2021 — CLEAR/KEYNOTE-581 (RCC) (median PFS 23.9 vs 9.2 months; OS HR 0.66).
- Makker V, et al. NEJM 2022 — KEYNOTE-775 (EC).
- Updated CLEAR OS analyses (ASCO/JCO abstracts).
- LENVIMA (lenvatinib) US Prescribing Information (2025): dosing, reduction and surgery warnings.
- KEYTRUDA (pembrolizumab) US Prescribing Information (2025) and HCP dosing page (q3w/q6w; 30 minutes).
- KEYTRUDA + LENVIMA HCP Dosing & Administration guide (EC pMMR).
- Lenvatinib: Impaired wound healing warning and surgical timing.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.